Hypertension
Conditions
Interventions
- Titration to Candesartan 12mg - Once daily - Treatment period: 8 weeks
- Change to Combination Tablets of candesartan 8mg / HCTZ 6.25mg - Once daily - Treatment period: 8 weeks
Sponsors
J-HOME-CARD Study group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The inclusion criteria for study patients: 1) Out-patient with essential hypertension, who has not been treated or treated with monotherapy. 2) Between 20 and 80 years of age 3) Patient understands study procedures and agrees to participate in the study by giving written informed consent prior to the study. 4) Patients with average home mornig systolic blood pressure >= 135mmHg after receving monotherapy with candesartan 8mg for four week or more.
Exclusion criteria
Exclusion criteria: Exclusion criteria 1) Secondary hypertension 2) Cardiac failure (above NYHA grade III) 3) Past history of major cardiac events or intervention (e.g., myocardial infarction, stroke) within 6 months prior to the start of the study. 4) Pregnancy (positive urine pregnancy test at pre-study) or breast feeding, or a female expecting to conceive within the study. 5) Critical liver damage 6) History of severe hepatic or renal disease (sCr>2.0 mg/dl) 7) Uncontrollable arrhythmia (atrial fibrillation, etc) 8) Hypersensitivity to ARB 9) Hypersensitivity to components of thiazide or similar compounds 10)Patient ineligible to this study due to other medical reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference of home morning systolic blood pressure reduction between two groups during eight-week treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Differences of home blood pressure reduction and differences of proportion achievement for target blood pressure level between two groups during eight-week treatment. 2) Differences of reduction in home nocturnal blood pressure during sleep between two groups during eight-week treatment. 3) Differences of clinic blood pressure reduction and differences of proportion achievement for target blood pressure level between two groups during eight-week treatment. 4) Differences of change in eGFR between two groups during eight-week treatment. 5) Differences of change in central blood pressure and augmentation index between two groups during eight-week treatment. 6) Changes in laboratory test results including LDL-C, K, sCr, uric acid, blood sugar, and HbA1c. | — |
Countries
Japan
Outcome results
None listed